Business, energy, technology, markets and global industry news from Business News Today

NeoImmuneTech

PharmaDeviceNews NeoImmuneTech
Tolerance Bio’s license for NeoImmuneTech’s clinical-stage long-acting interleukin-7 therapy efineptakin alfa strengthens its push into thymic function and immune-resilience research, bringing an established human-stage asset into its emerging thymus-focused pipeline. Representative image.
Pharma & Biotech

Tolerance Bio has found a faster route into the clinic, but can efineptakin alfa protect thymic function?

Tolerance Bio licenses efineptakin alfa from NeoImmuneTech, adding clinical-stage IL-7 to its thymus and immune-resilience strategy.

Read More
Representative image of sickle cell disease research and treatment. This article explores how NeoImmuneTech’s U.S. licensing deal for Endari could reshape the commercial landscape for sickle cell therapies in North America.
Pharma & Biotech

NeoImmuneTech takes over Endari’s U.S. rights from Emmaus: What this signals for the future of sickle cell treatment

NeoImmuneTech takes over U.S. rights for Endari from Emmaus Life Sciences. Find out what this deal reveals about the future of sickle cell treatment.

Read More